The patent application US20220259209A1, filed by Pfizer Inc., details methods for treating or preventing inflammatory skin conditions, specifically atopic dermatitis, using abrocitinib [1]. Abrocitinib is an oral selective Janus kinase 1 (JAK1) inhibitor [1][2]. The patent focuses on specific dosing regimens and combinations of abrocitinib with other compounds to enhance its efficacy [1].
How is abrocitinib administered according to this patent?
This patent application describes methods for administering abrocitinib, including specific oral dosage forms. It suggests that abrocitinib can be formulated for once-daily administration to achieve a desired therapeutic effect in treating inflammatory skin conditions like atopic dermatitis [1].
What specific conditions does this patent application address?
The primary focus of US20220259209A1 is the treatment and prevention of inflammatory skin conditions. Atopic dermatitis is specifically mentioned as a target condition for the abrocitinib-based therapies described [1].
What is the mechanism of action for abrocitinib?
Abrocitinib functions as a selective Janus kinase 1 (JAK1) inhibitor. JAK1 is involved in signaling pathways that contribute to inflammation in conditions such as atopic dermatitis. By inhibiting JAK1, abrocitinib aims to reduce this inflammatory response [1][2].
When does the patent for abrocitinib expire?
Information on the specific patent expiration date for abrocitinib is not directly available within US20220259209A1. However, patent expiry data for abrocitinib can be found on specialized patent tracking websites like DrugPatentWatch.com [3].
How does abrocitinib compare to other treatments for atopic dermatitis?
While this patent application focuses on abrocitinib, it implies that abrocitinib offers an advantage for atopic dermatitis. Abrocitinib is an oral JAK1 inhibitor, positioning it alongside other targeted therapies for moderate to severe atopic dermatitis [1][2]. The patent suggests specific advantages through its described dosing and combination methods.
Are there any safety concerns associated with abrocitinib?
The patent application itself does not detail safety concerns. However, as a JAK inhibitor, abrocitinib may carry a risk of serious side effects, including infections, blood clots, cardiovascular events, and certain cancers, as identified in broader prescribing information for this class of drugs [2].
Who manufactures abrocitinib?
Pfizer Inc. is the assignee of the patent application US20220259209A1, indicating their involvement in the development and potential manufacturing of abrocitinib [1].
What is the regulatory status of abrocitinib?
Abrocitinib has received regulatory approval in various regions for the treatment of atopic dermatitis. For instance, it is approved by the U.S. Food and Drug Administration (FDA) under the brand name Cibinqo [2].
What are the key patents protecting abrocitinib?
US20220259209A1 is a patent application detailing specific methods of use and formulations. The core compound and its initial uses are likely protected by earlier patents. Comprehensive patent landscapes for abrocitinib can be researched through patent databases and specialized services like DrugPatentWatch.com [3].
Sources:
[1] https://patents.google.com/patent/US20220259209A1
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-cibinqo-abrocitinib-treatment-atopic-dermatitis
[3] https://drugpatentwatch.com/